Oct 2, 2025 · Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of …

This designation entitles Alterity to seven years of market exclusivity in the U.S. and ten years of market exclusivity in the EU and qualifies Alterity for various development incentives, including …

Jan 29, 2025 · Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been …

Alterity Therapeutics was incorporated in Melbourne, Australia in 1997 as Prana Biotechnology and has offices in Melbourne, Australia, and San Francisco, USA. The Company listed on the …

At Alterity, we are focused on “changing the state” of people living with neurodegenerative diseases, from disease → health. We do this by targeting the underlying pathology to …

Jul 28, 2025 · Alterity recently reported positive data for its lead asset, ATH434, in a Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive …

Sep 15, 2025 · Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with …

Oct 9, 2025 · Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with …

Sep 29, 2025 · Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with …

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, …